GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Cyclically Adjusted Revenue per Share

Fortress Biotech (FRA:CNB1) Cyclically Adjusted Revenue per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fortress Biotech's adjusted revenue per share for the three months ended in Mar. 2024 was €1.341. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Fortress Biotech's average Cyclically Adjusted Revenue Growth Rate was 2.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Fortress Biotech was 9.20% per year. The lowest was 9.20% per year. And the median was 9.20% per year.

As of today (2024-05-27), Fortress Biotech's current stock price is €4.131. Fortress Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.00. Fortress Biotech's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fortress Biotech was 9.65. The lowest was 0.12. And the median was 1.51.


Fortress Biotech Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Fortress Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Cyclically Adjusted Revenue per Share Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.40 8.05 9.03 -

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.83 9.75 9.88 - -

Competitive Comparison of Fortress Biotech's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PS Ratio falls into.



Fortress Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fortress Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.341/131.7762*131.7762
=1.341

Current CPI (Mar. 2024) = 131.7762.

Fortress Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.180 99.621 0.238
201506 0.000 100.684 0.000
201509 0.008 100.392 0.011
201512 0.118 99.792 0.156
201603 0.224 100.470 0.294
201606 0.747 101.688 0.968
201609 0.325 101.861 0.420
201612 4.462 101.863 5.772
201703 15.525 102.862 19.889
201706 16.693 103.349 21.285
201709 14.489 104.136 18.335
201712 -35.214 104.011 -44.614
201803 1.689 105.290 2.114
201806 2.017 106.317 2.500
201809 1.484 106.507 1.836
201812 2.750 105.998 3.419
201903 1.347 107.251 1.655
201906 2.285 108.070 2.786
201909 2.341 108.329 2.848
201912 2.518 108.420 3.060
202003 2.762 108.902 3.342
202006 1.838 108.767 2.227
202009 1.586 109.815 1.903
202012 2.124 109.897 2.547
202103 1.806 111.754 2.130
202106 2.744 114.631 3.154
202109 3.305 115.734 3.763
202112 2.901 117.630 3.250
202203 3.778 121.301 4.104
202206 3.020 125.017 3.183
202209 2.801 125.227 2.948
202212 2.560 125.222 2.694
202303 1.709 127.348 1.768
202306 2.175 128.729 2.226
202309 4.345 129.860 4.409
202312 2.046 129.419 2.083
202403 1.341 131.776 1.341

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Fortress Biotech  (FRA:CNB1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Fortress Biotech was 9.65. The lowest was 0.12. And the median was 1.51.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fortress Biotech Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Industry
Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines